Objectives The objectives of this study were to finalize, develop the scoring, and explore the psychometric properties of the ACCEPTance by the Patients of their Treatment (ACCEPTÓ) questionnaire, as well as to provide the first elements for its interpretation and guidance for its future use. Methods ACCEPTÓ was finalized according to reference methods including testing in a pilot study, i.e., a multicenter, observational, longitudinal study conducted in France, in collaboration with a network of pharmacists. Principal component analysis using Varimax rotation was performed. The loadings of items on components in the principal component analysis were used to inform item selection. Validity of the measurement model of ACCEPTÓ was confirmed using Multi-trait/Multi-item Analysis based on item-scale Spearman correlations. Internal consistency reliability of the questionnaire was assessed by determining the Cronbach's a coefficient. Linear and logistic regressions were used to identify predictors of general acceptance, and to study predictors of persistence.
Introduction
In long-term therapy, it is important to understand the extent to which patients favor their treatment or not, and to be able to monitor to what extent they are willing to accept their medication regimen. It has been shown that non-adherence to treatment is a worldwide problem [1] , representing a great shortfall for both the patients and health organizations. In developed countries, adherence to longterm therapies in the general population is around 50 % and is much lower in developing countries [1] .
Numerous attempts to explain adherent and non-adherent behaviors have been made [2] [3] [4] [5] . Described as a multifactorial behavior, adherence is related to external factors (i.e., health system, social and economic factors, therapy factor) as well as to patient-related factors [1] . Several studies, based on the Health Beliefs Model [6] , have demonstrated how beliefs, concerns, and the perceived necessity of a treatment play a major role in adherence [2, 4, 7, 8] . The balance between positive and negative aspects of treatment is an important determinant of whether patients will adhere to and continue with their treatment [9] [10] [11] . These studies have reinforced the idea that patients' personal experiences with their medication is critical to explaining their decision to take it or not.
In a previous publication [12] , we have shown that patients frequently had an opinion on the drug they are taking, but denied judging its legitimacy. As a result of our qualitative research, we have defined patients' acceptance of their medication as the result of the balance between benefits (advantages) and risks (disadvantages) as rated by the patients, based on their personal experience with their treatment. Figure 1 illustrates our conceptual model of acceptance.
Acceptance differs from satisfaction, which compares experience with expectations [13] . It also differs from adherence, as it focuses on patients' own experience and beliefs about their treatment rather than on the agreement with their physician's recommendations. Acceptance will determine patients' behavior towards their treatment, i.e., their adherence and persistence (defined as ''the duration of time from initiation to discontinuation of therapy'' [14] ). Acceptance might also be the closest concept to an individual benefit-risk assessment.
On the regulatory perspective, acceptance/acceptability has been recently integrated in a European Medicines Agency (EMA) guideline. The EMA advises sponsors to investigate it in the development of medicines for pediatric use [15] . The EMA has made it mandatory to ensure that a child's acceptance is assessed, with clear and explicit expectations regarding the detailed conceptual content of ''acceptance.'' The Therapeutic Goods Administration of Australia is one example of a regulatory authority including such an outcome in a market authorization label, i.e., acceptability is mentioned in the safety section of INTANZA Product Information (ARTG ID 150130) [16] .
As a result of our qualitative study [12] , we have developed the ACCEPTance by the Patients of their Treatment (ACCEPTÓ) questionnaire, an original generic patient-reported measure that evaluates patients' acceptance of long-term medication. It is intended to be specific to the concept of acceptance, but not treatment specific.
The objectives of this study were to finalize, develop the scoring, and explore the psychometric properties of the ACCEPTÓ questionnaire, as well as to provide the first elements for its interpretation and guidance for its future use.
Methods

Study Design and Population
In 2013, a multi-center, observational, longitudinal study was conducted in France, in collaboration with a network of pharmacists, to finalize and provide evidence of validation of the ACCEPTÓ questionnaire in the population tested. One-hundred and thirty-three pharmacists (55.6 % male, 44.4 % female) from 21 metropolitan French regions (of note, in 2013, there were in total 22 regions in metropolitan France) were asked to recruit patients. Most of them (92.8 %) were incumbents with a homogeneous repartition on the French territory. To be included, patients needed to be aged C18 years, going to the pharmacy to initiate, change, or renew a medicine prescribed for a chronic disease (i.e., anti-diabetic drugs, statins, antihypertensives [except b-blockers], antiretroviral therapy, antiasthma drugs, b-blockers [for cardiac failure, angina, coronary thrombosis, and rhythm disturbance], anti-osteoporotic drugs, antiplatelet agent or anti-vitamin K, antitumor necrosis factor [all indications], and oral corticosteroid therapy). Patients had to regularly buy their medicines in the same pharmacy. For each patient, pharmacists had to have already performed at least three deliverances whatever the treatment. Patients were not included if they were enrolled in a clinical trial, unable to take part in the study because of physical, mental, or linguistic major problems, or if they frequented several pharmacies. Patients were asked to complete the pilot version of the ACCEPTÓ questionnaire (32 items) [12] and the Morisky Medication-Taking Adherence Scale (MMAS-4) [17] at months 1 (M1), 3 (M3), and 6 (M6) (Fig. 2) . Persistence was evaluated at M3 and M6. Patients had to answer the following question: ''Are you taking your treatment still?'' If the answer was no, reasons for stopping were proposed (i.e., normal end of treatment, change of treatment by doctor, discontinuation decided by patient, other reason).
Measures
AcceptÓ
The pilot version of the ACCEPTÓ questionnaire was developed in French, and contained 32 items. Items 1-28 included categorical response options (e.g., Yes, and I don't find this easy to accept; Yes, but I find this easy to accept; No). In addition to these three responses, items 24-26 included a ''don't know'' option. Items 29-32 use ordinal, Likert-type, response options (4-point Likert) plus an ''I don't know'' option. According to the initial conceptual framework, items were grouped into six main dimensions: ''Your medication'' (five items), ''Duration of treatment'' (two items), ''Constraints'' (11 items), ''Sideeffects'' (six items), ''Efficacy'' (four items), and ''Global acceptance'' (four items).
MMAS-4
The MMAS-4 is a generic, self-reported, medication-taking behavior scale in which the specific health issue (e.g., high blood pressure, diabetes mellitus, elevated cholesterol, human immunodeficiency virus, contraception) is inserted for the ''health concern.'' [17] The MMAS-4 consists of four items with a scoring scheme of ''Yes'' = 0 and ''No'' = 1. The items are summed to give a range of scores from 0 to 4 with 0 = lowest adherence, and 4 = highest adherence.
Statistical Analyses and Psychometric Properties
Long-term treatments were grouped into three categories: To provide a preliminary measurement framework of ACCEPTÓ, a factorial approach was chosen to analyze the questionnaire in its entirety. Principal component analysis (PCA) using Varimax rotation was performed and interpreted in the light of the conceptual framework developed previously [12] . The rationale for using PCA was to explore the relationship between items from a statistical perspective and to aid discussions between all authors in [18] . The loadings of items on factors in the PCA were used to inform item selection (i.e., item loading [0.4). Although this finalization process was supported by statistical results, decisions on the item selection and creation of scores were made after careful interpretation based on item content and the hypothesized conceptual model. Validity of the measurement model of ACCEPTÓ was confirmed using Multi-trait/Multi-item Analysis based on item-scale Spearman correlations [19] . This method is based on the analysis of the correlations between each item and each subscale. Two criteria are generally assessed: (1) item convergent validity criterion, where the correlation between each item and its own scale corrected for overlap should be at least 0.40 [20] ; and (2) item discriminant validity criterion, where each item should correlate significantly higher with its hypothesized domains than with other domains. Pearson correlation coefficients (r) were calculated to explore scale-scale correlations.
Internal consistency reliability of the questionnaire was assessed by determining the Cronbach's alpha coefficient [21] : a value of 0.70 or above was considered satisfactory for group comparisons [22] . Because of the study design (i.e., recruitment by pharmacists making it impossible to measure changes in patients' clinical condition), test-retest reliability was not assessed.
Linear and logistic regressions were used to explore links between general acceptance and other dimensions, i.e., to identify predictors of general acceptance, and to study predictors of persistence, which was defined as the act of continuing the treatment for the prescribed duration.
Results
Population Characteristics in the Validation Study
A total of 189 patients were included. Overall, the mean age was 62 years, with a majority of female patients (53.4 %) ( Table 1) . Of the 189 patients included, 161 at M1, 167 at M3, and 156 at M6 were retained in the evaluable population.
Item Reduction Process and Finalization
Quality of Completion
More than 70 % of patients completed all ACCEPTÓ items. All data combined, only six items out of 32 had 5-10 % of missing data (items 7, 20-23, and 28).
Distribution of Answers
The distribution of the responses was skewed towards the most positive response options for a majority of items (n = 17,[60 %). The items with the most severe skewness in their response distribution were listed and appraised to determine whether they should be deleted from the questionnaire or whether they tapped into a key concept that could not be absent from the final questionnaire. Five items with consistent and severely skewed distribution at M1, M3, and M6 were identified, i.e., items 3, 8, 16, 27, and 31 (Table 2 ). These items were considered for potential deletion from the questionnaire, but the decision had to be made also in light of the results of the PCA and the Cronbach's a, and of the hypothesized conceptual model.
Principal Component Analysis
The PCA extracted nine components (see Online Resource 1 for data). Only five of them seemed to be interpretable in the light of the conceptual framework. Another PCA with five components was performed (see Following this analysis, it was decided to delete items 4, 5, 17, and 23, for poor component loading, and items 27 and 31 for both skewed distribution and poor component loading. Item 14 (Do you find that you have a lot of medications to take?), which also exhibited a poor loading in component 4, raised considerable discussion. At that time of the analysis, it was decided that its upholding in the questionnaire should be decided following the calculation of the Cronbach's a with and without its maintenance in the Acceptance/Regimen Constraint dimension. The other alternative was to keep it as a single-item dimension because of the relevance of the item content on the conceptual level.
Item 8 (Do you find the times at which you have to take your medication an inconvenience in your everyday routine?), which exhibited a high component loading in component 5 was also the subject of much discussion because of the skewed distribution of answers. It was decided that the calculation of the Cronbach's a with and without its maintenance in the Acceptance/Long-term Treatment dimension would be helpful to make a decision about its upholding in the final questionnaire.
The relevance of item 9 (Do you find that having to remember to take your medication is inconvenient?) in the Acceptance/Long-term Treatment dimension was also debated because its content would rather link it to the Acceptance/Regimen Constraints dimension. As suggested for items 8 and 14, it was decided that the exploration of Cronbach's a with and without its maintenance in the Acceptance/Long-Term Treatment and Acceptance/Regimen Constraints dimensions would be helpful to make the decision.
Component 1 of the PCA was split into two dimensions, i.e., Acceptance/General (29, 30, 32) and Acceptance/Effectiveness (25, 26, 28) in light of the items content and hypothesized conceptual model.
Cronbach's a
Deleting item 9 to the Acceptance/Regimen Constraints dimension lowered the a from 0.82 to 0.79 (all data combined), and adding item 14 lowered the a to 0.72 (all data 
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SD standard deviation Validation of the ACCEPTÓ Questionnairecombined). Adding item 9 to the Acceptance/Long-term Treatment dimension raised the a from 0.67 to 0.70 (all data combined). Based on those results and on the conceptual content of the item, it was decided to keep item 9 in the Acceptance/Regimen Constraints dimension and consider item 14 as a single-item dimension.
Adding item 8 to the Acceptance/Long-Term Treatment dimension generated a raise of the Cronbach's a from 0.67 to 0.69 (all data combined). This gain in a was weighed against item content and skewness in distribution leading to the decision of excluding item 8 from the ACCEPTÓ questionnaire.
At this stage of the analysis, we confirmed the structure of ACCEPTÓ: 25 items, with 24 items distributed in six dimensions and one single-item dimension (Table 3 ). All items within a dimension are equally weighted in the calculation of the dimension score. This applies by definition to the single-item dimension. After aggregation of the items in their dimension to form a score, the dimension score is re-scaled on a 0-100 range by simple linearization, which does not affect the item weighting. The single-item dimension score is not rescaled, therefore keeping a range of 1-3. Of note, no global score is calculated.
Validation of the Confirmed Structure
of the ACCEPTÓ Questionnaire
Internal Consistency Reliability
Results are presented as all data combined (M1 ? M3 ? M6) for each treatment category (i.e., PP, SP, and SYM). Internal consistency reliability of the majority of multi-item scores was good, above the threshold value of 0.70 for four dimensions and close to it for two dimensions (i.e., Acceptance/Long-Term Treatment, a = 0.67; Acceptance/Effectiveness, a = 0.68) ( Table 4 ). In particular, the Cronbach's a of the Acceptance/General dimension was high (0.84).
When analyzing each category of treatments (PP, SP, and SYM), Acceptance/Medication Inconvenience, Acceptance/Regimen Constraints, Acceptance/Side Effects, and Acceptance/General dimensions showed good internal consistency reliability (Cronbach's a [ 0.70) for all three categories. Acceptance/Long-Term Treatment dimension showed better internal consistency reliability results for primary and secondary prevention treatments than for symptomatic treatments. Contrary to Acceptance/Long-Term Treatment dimension, Acceptance/Effectiveness dimension showed better internal consistency reliability results for symptomatic treatments than for primary and secondary prevention treatments.
Validity
3.3.2.1 Multi-trait/Multi-item Analysis Overall, the majority of items met convergent and discriminant validity criteria (Table 5 ). All items of the Acceptance/ General, Acceptance/Regimen Constraints and Acceptance/Effectiveness dimensions met the convergent validity criterion. One item of the Acceptance/Side Effects dimension and one item of the Acceptance/ Long-term Treatment dimension did not meet the criterion. All items of the Acceptance/General, Acceptance/Regimen Constraints, Acceptance/Side Effects, and Acceptance/Medication Inconvenience dimensions met the discriminant validity. One item of the Acceptance/Long-Term Treatment dimension and two items of the Acceptance/Effectiveness dimension did not meet the criterion. For primary prevention treatments, results were similar to results of the analysis grouping all treatments. The only major difference was for the Acceptance/Effectiveness dimension in which only one item met the convergent validity criterion and no item met the discriminant validity criterion.
For secondary prevention treatments, results were similar to results of the analysis grouping all treatments. The only major difference was for the Acceptance/ Medication Inconvenience dimension in which only two items met both the convergent and discriminant validity criteria.
For symptomatic treatments, results were similar to results of the analysis grouping all treatments. The only major difference was for the Acceptance/Long-Term Treatment dimension in which only one item met both the convergent and discriminant validity criteria.
Inter-dimension Correlations Correlations of
Acceptance/General dimension with other ACCEPTÓ dimensions for all data combined ranged from 0.02 with Acceptance/Medication Inconvenience to 0.58 with Acceptance/Effectiveness (Table 6 ). These correlations varied according to each treatment category, e.g., 0.07 with Acceptance/Side Effects for SP vs. 0.22 for all data combined. Interestingly, very low correlations were noted with Acceptance/Medication Inconvenience (0.02), and with Acceptance/Regimen Constraints (0.07) for all types of treatments. 
Description of Scores
Description of ACCEPTÓ Dimension Scores
For symptomatic treatments, scores were lower than scores of primary and secondary prevention treatments for all ACCEPTÓ dimensions except Acceptance/Regimen Constraints (Fig. 3) .
Description of MMAS-4 Scores
Overall, adherence was good for all treatment categories, at each time and for all data combined (Table 7) .
Description of Persistence
Persistence was evaluated at M3 and M6. Patients had to answer the following question: ''Are you taking your treatment still?'' If the answer was no, reasons for stopping were proposed (i.e., normal end of treatment, change of treatment by doctor, discontinuation decided by patient, other reason). At M3, persistence was very good, with 92.9 % for primary prevention, 97.1 % for secondary prevention, and 90.2 % for symptomatic treatment. Change of treatment by doctor was the main reason for discontinuation. At M6, persistence was still high with a slight decrease for secondary prevention (i.e., 94 % for primary, 89.6 % for secondary, and 92.1 % for symptomatic).
Linear and Logistic Regressions
For all data combined, results of the linear regressions showed that the Acceptance/General score was significantly explained by the scores of Acceptance/Long-Term Treatment, Acceptance/Side Effects, Acceptance/Effectiveness, and Acceptance/Numerous Medications (Table 8 ). In addition, Acceptance/General at M6 was strongly predicted by the score of Acceptance/Effectiveness at M1 and M3, and significantly but to a lesser extent predicted by the scores of Acceptance/Side Effects and Numerous Medications at M1 and M3. However, persistence at M3 and M6 was not explained by any of the seven ACCEPTÓ scores at M1 and M3. M6 MMAS-4 adherence score was significantly predicted by the M1 Acceptance/ Effectiveness score and by M3 Acceptance/Medication Inconvenience and Acceptance/Regimen Constraints.
Discussion
Patients' behavior towards their treatment is determined by their beliefs, perceptions, and experiences with their treatment. Beliefs and perceptions are specifically measured by existing patient-reported outcome questionnaires [8, 17, 23] . The ACCEPTÓ questionnaire completes this set of existing questionnaires by introducing the concept of acceptance, hypothesized as the balance between benefits (advantages) and risks (disadvantages) of the treatment as rated by the patients based on their personal experience of their treatment. This concept emerged during our qualitative phase of research [12] . The originality of ACCEPTÓ resides in the fact that it is not specific to a treatment or a disease but to a concept, contrary to other measures such as the Vaccinees' Perception of Injection (VAPIÓ), which is specific to influenza vaccination [24] or the Treatment Evaluation Questionnaires (TEQ) specific to sleep disorders [25] . The development of ACCEPTÓ followed a rigorous and recommended procedure, based on in-depth interviews and subsequent comprehension testing with patients [12] . The final version of ACCEPTÓ is composed of 25 items, distributed in seven dimensions providing a comprehensive appraisal of acceptance of long-term medication, with six scores measuring acceptance of treatment-specific attributes and one score measuring general treatment acceptance. The main specificity of the ACCEPTÓ questionnaire is that treatment attributes are measured from the ''how easy it is to accept'' perspective, rather than being compared with previous expectations (as in satisfaction questionnaires) or assessed at quantity or frequency levels, i.e., ''how often, how much.'' ACCEPTÓ was developed in French for France and linguistically validated in 16 other languages (see detailed list of languages at http://www.proqolig.org). Therefore, its implementation in international studies is possible to explore acceptance for a given treatment in different countries and allow for comparisons across countries.
The measurement properties of ACCEPTÓ were overall fairly satisfactory. The Acceptance/General dimension had a very good Cronbach's a across all measures (M1, M3, Table 7 MMAS-4 scores at M1, M3, and M6, and all data combined for each treatment category M1 (0) 70 (0) 38 (2) 159 (2) 55 (0) 69 (0) 37 (4) 163 (4) 50 (0) 65 (2) 34 (3) 51 (5) Mean ( 155 (0) 204 (2) 109 (9) 473 (11) Mean ( and M6) and all categories of treatments (PP, SP, and SYM), confirming its relevance in evaluating the level of treatment acceptance by the patients. In contrast, the Acceptance/Long-Term Treatment dimension did not function very well (low Cronbach's a). However, the information provided by each individual item comprising this dimension should not be discarded, in particular the information provided by item 13 (Do you find that having to take your medication regularly has become part of your normal routine?). Exploring daily routine might be important because several authors have reported that the ''fit'' of the regimen into an individual's daily routine is another important determinant of adherence [26] [27] [28] . The low correlations between Acceptance/General and the other dimensions confirm that ACCEPTÓ measures distinct attributes. Furthermore, these correlations vary according to each treatment category, indicating that ACCEPTÓ captures the heterogeneity in populations and treatment. The very low correlations of the dimensions of Acceptance/Regimen Constraints and Acceptance/Medication Inconvenience with Acceptance/General may indicate that any improvement on those dimensions would have a very low impact on treatment acceptance in general. In contrast, the dimensions of Acceptance/Effectiveness and Acceptance/Side Effects have much higher correlations with Acceptance/General. This may indicate that improvements on Effectiveness and Side Effects are more important for patients' acceptance of treatment than improvements on inconvenience and constraints of medication. The heterogeneity of the population (with three different treatment categories) is likely to mask the existence of disease-specific explicative patterns. These results call for more studies on more homogeneous populations to assess the level of acceptance in a specific therapeutic area for instance.
Regressions showed that Acceptance/Effectiveness is a predictor of general acceptance. However, no predictor of persistence could be identified. The inability of explaining persistence by any of the scores of ACCEPTÓ could be explained by a lack of study power, and would suggest performing other studies on more important and more homogeneous populations.
Finally, test-retest reliability and responsiveness to change need to be assessed in future studies.
The structure of ACCEPTÓ enables the interpretation of scores on three different levels: (1) a first level of general treatment acceptance with the score of the Acceptance/ General dimension; (2) a second level corresponding to the scores of each treatment-specific attribute (i.e., Acceptance/Medication Inconvenience, Acceptance/Long-Term Treatment, Acceptance/Regimen Constraints, Acceptance/ Side Effects, Acceptance/Effectiveness, and Acceptance/ Numerous Medications); and (3) a third level related to the analysis of each item corresponding to specific features within each dimension. The goal is to facilitate the identification of treatment attributes where improvements might be needed.
The ''Don't know'' response option available in items 19 (Acceptance/Side Effects), 20 and 21 (Acceptance/Effectiveness), and 23-25 (Acceptance/General) might provide interesting information about the level of knowledge of patients about their treatment. A high number of ''Don't know'' answers could be an indicator of a lack of information from or training by physicians, and might provide room for action to improve treatment information given to the patients. It could also be an indication of some features or attributes that are not known to patients neither as an experience nor as a belief (e.g., efficacy in cancer). By measuring medication acceptance of patients based on their experience, the ACCEPTÓ questionnaire fills a gap in the understanding of patients' behavior in the medication-taking process. Acceptance is particularly interesting in terms of monitoring diseases with long-term treatments such as chronic diseases, diseases with silent or less bothersome symptoms, and conditions with risk factors necessitating long-term therapy. It will enable the collection of data on predictors of adherence and persistence based on self-reported patients' experience. ACCEPTÓ also may facilitate the collection of ''real-world data'' on product perception in the market early on. We are currently analyzing data from an observational cross-sectional study conducted through the French Carenity platform in more than 4000 patients with several chronic diseases. This first of its type study enabled ACCEPTÓ data to be collected in real life for a variety of chronic diseases. These data may help to evaluate and interpret the level of acceptance in future studies and give indications about patient priorities and current unmet needs.
Finding factors linked to patients' adherence is strategic in an environment where different formulations or administration schemes exist, risk-to-benefit ratios of treatment are different, and generics are available. ACCEPTÓ will be useful as a particular surrogate of adherence within pharmacoepidemiological studies. This is especially important because patients are hard to identify and assess once they become non-adherent. This would allow assessment of the way that attributes of long-term medications influence patients' behavior. ACCEPTÓ can inform researchers and clinicians about patients' perceptions and beliefs that are not in favor of adherence before patients become non-adherent and become not accessible to care and studies. In addition, ACCEPTÓ delivers both an evaluative score and an access to explicative factors, allowing targeted interventions to be designed at the individual level (such as a change in dosage) or at the population level (such as more education).
Conclusion
The self-administered ACCEPTÓ questionnaire provides valid and reliable scores for the assessment of patients' acceptance of long-term medication. Disease-specific and large prospective studies are needed to assess the ability of ACCEPTÓ to predict persistence with treatment. In future studies, ACCEPTÓ data may help to evaluate and interpret the level of acceptance and give indications about patient priorities about their treatment and current unmet needs.
